Article · Wikipedia archive · Last revised Jun 9, 2026

TACT833

TACT833 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. The exact chemical structure of TACT833 does not yet appear to have been disclosed, but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.

Last revised
Jun 9, 2026
Read time
≈ 1 min
Length
260 w
Citations
13
Source
Wikipedia ↗
TACT833
Clinical data
Other namesTACT-833
Drug classMonoamine transporter modulator; Serotonin 5-HT1B receptor modulator
ATC code
  • None

TACT833 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder.1234 It is being developed by Tactogen.1234 As of the first quarter of 2025, the drug is in the preclinical research stage of development.123 The exact chemical structure of TACT833 does not yet appear to have been disclosed,4 but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB.5

See also

See also

References

References

  1. "Delving into the Latest Updates on TACT411/833 with Synapse". Synapse. 14 June 2025. Retrieved 25 November 2025.
  2. Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  3. "Tactogen Inc – Pipeline". Tactogen Inc. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523.
  4. Matthew Baggott, Tactogen (14 November 2025). Progress in Novel Entactogens as Therapeutics. 5th Annual Conference on Psychedelics and Psychedelic Medicine, Virtual, November 14-15, 2025. Massachusetts General Hospital. Archived from the original on 8 August 2025. Retrieved 25 November 2025.{{cite conference}}: CS1 maint: bot: original URL status unknown (link)
  5. US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published 2023 May 18, assigned to Tactogen